Gammagard
Links shared publicly online about this topic
GAMMAGARD LIQUID (Immune globulin) drug information from MPR
empr.com — “GAMMAGARD LIQUID (Immune globulin) drug information for Immunodeficiency from MPR including side effects, drug interactions, dosing, contraindications and precautions.” View full resource at empr.com
Most Recently Shared on August 17, 2010 at 4:49 am By:
MPR News: GAMMAGARD LIQUID: Monograph added. http://bit.ly/cjMb3D
Gammagard Liquid Approved for SC Administration - MPR
empr.com — “Baxter announced that Gammagard Liquid (immune globulin infusion [human]) has been approved for subcutaneous administration, which allows patients to self-administer the therapy at home.” View full resource at empr.com
Most Recently Shared on July 25, 2011 at 9:10 pm By:
Gammagard Liquid Approved for SC Administration http://bit.ly/qWvyKV #immunesystem
FDA Alert: GammaGard Liquid, Immune Globulin Intravenous (Human)
drugs.com — “FDA Alert: GammaGard Liquid, Immune Globulin Intravenous (Human)” View full resource at drugs.com
Most Recently Shared on June 8, 2010 at 11:05 pm By:
FDA Alert - Market Withdrawal: GammaGard Liquid - http://bit.ly/aIIVtb
Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration
news-medical.net — “Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.” View full resource at news-medical.net
Most Recently Shared on July 25, 2011 at 2:27 pm By:
Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration: Baxter International Inc. ... http://bit.ly/oKSwTf
Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's
news-medical.net — “Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.” View full resource at news-medical.net
Most Recently Shared on January 24, 2012 at 10:09 am By:
Obesity News: Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's: Baxter International In... http://t.co/7qXnHCWp
GammaGard Liquid withdrawn from market - MPR
empr.com — “The FDA and Baxter BioScience have notified healthcare professionals of a voluntary market withdrawal being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions associated with two lots of GammaGard Liquid (immune globulin intravenous [human]).” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 3:05 pm By:
GammaGard Liquid withdrawn from market: The FDA and Baxter BioScience have notified healthcare professionals of a ... http://bit.ly/bRtZKB
Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN
news-medical.net — “Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.” View full resource at news-medical.net
Most Recently Shared on January 10, 2012 at 4:34 am By:
Meningitis News: Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN: Baxter International Inc. tod... http://t.co/0XXeRkJG
Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency
drugs.com — “Gammagard (immune globulin infusion (human)) is used for the treatment of primary immunodeficiency disorders. Information from Drugs.com, includes Gammagard side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 25, 2011 at 11:38 pm By:
FDA Approves Subcutaneous Route of Administration for Gammagard Liquid - http://bit.ly/oag3KB
Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency
drugs.com — “Gammagard (immune globulin infusion (human)) is used for the treatment of primary immunodeficiency disorders. Information from Drugs.com, includes Gammagard side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 25, 2011 at 11:06 pm By:
Drugs and Devices OW OW Health
Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients wi... http://bit.ly/orGGTk #drug
MediGuard.org - Gammagard | Drug safety information | Monitoring more than 120 patients
mediguard.org — “MediGuard.org - Gammagard | Drug safety information | Monitoring more than 120 patients” View full resource at mediguard.org
Most Recently Shared on February 25, 2011 at 10:17 pm By:
MediGuard.org Health Organization
89% of patients taking #gammagard use it for Immune Deficiency ... http://tinyurl.com/49tsmkw
Baxter U.S. - Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
baxter.com — “Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency” View full resource at baxter.com
Most Recently Shared on July 25, 2011 at 1:07 pm By:
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Pri... http://bit.ly/mPNIjk
Baxter And New York-Presbyterian/Weill Cornell Announce 18-Month Data From Phase II Study Of GAMMAGARD In Patients With Alzheimer's Disease
medicalnewstoday.com — “Baxter International Inc. (NYSE: BAX) and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGA” View full resource at medicalnewstoday.com
Most Recently Shared on April 15, 2010 at 1:11 pm By:
MNT Alzheimer's News Health News
Baxter And New York-Presbyterian/Weill Cornell Announce 18-Month Data From Phase II Study Of GAMMAGARD In Patients Wit... http://mnt.to/3BfJ
Baxter U.S. - Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Nueropathy at AAN Annual Meeting
baxter.com — “Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Nueropathy at AAN Annual Meeting” View full resource at baxter.com
Most Recently Shared on April 27, 2012 at 1:20 pm By:
Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annu... http://t.co/eYXDsLbl
Baxter U.S. -Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological Disorder
baxter.com — “Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, A Degenerative Neurological Disorder” View full resource at baxter.com
Most Recently Shared on January 9, 2012 at 2:39 pm By:
Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, A Degenera... http://t.co/MX3B3k3D
Baxter U.S. - Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer's Disease
baxter.com — “Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer's Disease” View full resource at baxter.com
Most Recently Shared on April 14, 2010 at 4:54 pm By:
eyeonfda Pharma and Health Lawyer
Phase 2 data from Baxter on GAMMAGARD in Patients with Alzheimer's - http://ow.ly/1yrFV
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
Advertisement
